Table 6.
Cox multivariate analysis of overall survival in all patients (n = 104).
| Variables |
Log-rank tesk |
Multivariate analysis | ||
|---|---|---|---|---|
| HR | 95% CI | P | ||
| Sex (male vs. female) | 0.554 | |||
| Age (≥49.5 years vs. <49.5 years) |
0.077 | 0.646 | 0.306–1.361 | 0.250 |
| Smoking history (yes vs. no) | 0.118 | |||
| Brain metastasis (yes vs. no) | 0.548 | |||
| Bone metastasis (yes vs. no) | 0.375 | |||
| Lung metastasis (yes vs. no) | 0.817 | |||
| Liver metastasis (yes vs. no) | 0.022 | 1.637 | 0.473–5.663 | 0.436 |
| Adrenal gland metastasis (yes vs. no) | 0.016 | 3.431 | 1.088–10.822 | 0.035 |
| Supraclavicular lymph node metastasis (yes vs. no) | 0.967 | |||
| Pleural metastasis (yes vs. no) |
0.173 | |||
| Metastasis (yes vs. no) | 0.314 | |||
| Metastasis (≥4 sites vs. <4 sites) |
0.037 | 0.637 | 0.151–2.681 | 0.539 |
| Adenocarcinoma (yes vs. no) |
0.044 | 0.159 | 0.031–0.798 | 0.026 |
| Crizotinib as first-line therapy (yes vs. no) | 0.406 | |||
| Tumor responses (CR/PR vs. SD/PD) |
0.0002990 | 0.552 | 0.251–1.215 | 0.140 |
| Intracranial progression (yes vs. no) |
0.909 | |||
| Intrathoracic progression (yes vs. no) | 0.008 | 3.112 | 1.374–7.049 | 0.007 |
| Bone progression (yes vs. no) |
0.0001670 | 2.604 | 0.993–6.827 | 0.052 |
| Crizotinib treatment time (≥16 vs. <16 months) | 8.5009000E−11 | 0.123 | 0.050–0.305 | 0.0000060 |